750 results on '"Thrombocytosis complications"'
Search Results
2. Extreme Reactive Thrombocytosis Caused by Obstructive Nephrolithiasis and Pyelonephritis.
- Author
-
Zhong J and Packer CD
- Subjects
- Humans, Male, Aged, 80 and over, Platelet Count, Anti-Bacterial Agents therapeutic use, Pyelonephritis complications, Pyelonephritis diagnosis, Thrombocytosis complications, Thrombocytosis diagnosis, Thrombocytosis blood, Nephrolithiasis complications, Nephrolithiasis diagnosis
- Abstract
Platelet counts in reactive thrombocytosis rarely exceed 1000 × 10
9 /L. We present the case of a male patient, aged 80 years, with quiescent rheumatoid arthritis who was found to have a platelet count of 1011 × 109 /L on routine laboratory testing. The patient was initially asymptomatic but developed leukocytosis to 23.1 × 109 /L on hospital day 2. Diagnostic work-up revealed obstructive nephrolithiasis and pyelonephritis, and the thrombocytosis and leukocytosis gradually resolved with empiric antibiotic treatment and ureteral stent placement. Tests for myeloproliferative disorders, including JAK-2V617F mutation, BCR-ABL for chronic myeloid leukemia and acute lymphocytic leukemia, and myeloproliferative neoplasms (MPL/CALR), were negative. Physicians should be aware that in rare cases reactive thrombocytosis can exceed 1000 × 109 /L, and that markedly elevated platelet counts in the setting of urinary tract infections may be an early sign of obstructive uropathy., (Copyright © 2024 Marshfield Clinic Health System.)- Published
- 2024
- Full Text
- View/download PDF
3. Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma.
- Author
-
Milojevic B, Janicic A, Grozdic Milojevic I, Grubor N, Bumbasirevic U, Radovanovic M, Radisavcevic D, Jovanovic D, Sretenovic M, Durutovic O, and Sipetic Grujicic S
- Subjects
- Humans, Prognosis, Kaplan-Meier Estimate, Neoplasm Recurrence, Local surgery, Retrospective Studies, Carcinoma, Transitional Cell complications, Carcinoma, Transitional Cell surgery, Urinary Bladder Neoplasms, Thrombocytosis complications, Urologic Neoplasms pathology
- Abstract
Background: The aim of this work was to evaluate the prognostic potential of preoperative thrombocytosis for recurrence-free survival (RFS) and cancer-specific survival (CSS) among patients subjected to radical nephroureterectomy (RNU) due to UTUC., Patients and Methods: Analytical cohort was composed of a single-center series of 405 patients treated between January 1999 and December 2020. Thrombocytosis was defined as a platelet count exceeding the threshold value of 400 × 10
9 per L. Along with the Kaplan-Meier survival probability, Cox proportional hazard regression models were used., Results: Preoperative thrombocytosis confirmed in 71 patients (17.5%) was significantly associated with the higher pathological tumor stage, lymph node metastasis, prior bladder cancer diagnosis, and preoperative anemia. With a median post-surgical follow-up period of 33.5 months, 125 patients (30.9%) experienced disease recurrence. The recurrence rate among patients with normal platelet levels was 13.6%, compared with 22.2% in those with preoperative thrombocytosis (p < 0.03). The 5-year RFS estimates reached 36.6% in the thrombocytosis-confirmed group. Multivariate analysis implied that preoperative thrombocytosis was a significant independent prognosticator of both poor RFS (HR 2.22, 95% CI 1.14-4.31, p = 0.02) and CSS (HR 2.48, 95% CI 1.14-3.09, p = 0.01)., Conclusions: Patients with a clinically significant elevation of platelet count prior to RNU were more likely to have UTUC with advanced tumor stages and lymph node metastases. Preoperative thrombocytosis was an independent predictor of RFS and CSS in patients who underwent radical nephroureterectomy. Furthermore, preoperative thrombocytosis may complement and refine UTUC clinical prediction algorithms as an independent indicator of adverse survival outcomes., (© 2024. Society of Surgical Oncology.)- Published
- 2024
- Full Text
- View/download PDF
4. Paraneoplastic Syndromes in Hepatocellular Carcinoma, Epidemiology, and Survival: A Retrospective Seven Years Study.
- Author
-
Burciu C, Sirli R, Bende R, Vuletici D, Miutescu B, Moga T, Bende F, Popescu A, Sporea I, Koppandi O, Miutescu E, Iovanescu D, and Danila M
- Subjects
- Humans, Male, Retrospective Studies, Female, Middle Aged, Aged, Prevalence, Adult, Survival Analysis, Hypercholesterolemia epidemiology, Hypercholesterolemia complications, Hypoglycemia epidemiology, Hypoglycemia complications, Polycythemia epidemiology, Polycythemia complications, Aged, 80 and over, Thrombocytosis epidemiology, Thrombocytosis complications, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular complications, Paraneoplastic Syndromes epidemiology, Paraneoplastic Syndromes mortality, Liver Neoplasms mortality, Liver Neoplasms epidemiology, Liver Neoplasms complications
- Abstract
Background and Objectives: Liver cancer poses a significant global health threat, ranking among the top three causes of cancer-related deaths. Patients with hepatocellular carcinoma (HCC) often present with symptoms associated with neoplasms or unusual clinical features such as paraneoplastic syndromes (PNS), including hypoglycemia, hypercholesterolemia, thrombocytosis, and erythrocytosis. Our study aimed to investigate the prevalence, clinical characteristics, and survival outcomes associated with PNS in HCC patients and assess each PNS's impact on patient survival. Materials and Methods: We conducted a retrospective analysis of PNS clinical features and survival among consecutive HCC patients diagnosed at our department over seven years, comparing them with HCC patients without PNS. The study involved a retrospective data evaluation from 378 patients diagnosed with HCC between January 2016 and October 2023. Results: We obtained a PNS prevalence of 25.7%, with paraneoplastic hypercholesterolemia at 10.9%, hypoglycemia at 6.9%, erythrocytosis at 4.5%, and thrombocytosis at 3.4%. Patients with PNS tended to be younger and predominantly male. Multivariate analysis revealed a strong correlation between PNS and levels of alpha-fetoprotein and tumor size, with diabetes also showing a significant statistical association ( p < 0.05). Subgroup analysis based on specific paraneoplastic syndromes demonstrated shorter survival in patients with PNS, albeit without significant statistical differences, except for hypoglycemia ( p < 0.0001). Matched analysis indicated a shorter survival rate for patients with PNS, although no significant statistical differences were observed. Conclusions: PNS are frequently observed in HCC cases and are associated with unfavorable prognoses and decreased survival rates due to their correlation with increased tumor burdens. However, they do not independently predict poor survival. The impact of individual PNS on HCC prognosis varies.
- Published
- 2024
- Full Text
- View/download PDF
5. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.
- Author
-
Loscocco GG, Gesullo F, Capecchi G, Atanasio A, Maccari C, Mannelli F, Vannucchi AM, and Guglielmelli P
- Subjects
- Humans, Male, Female, Middle Aged, Leukocytosis complications, Mutation, Janus Kinase 2 genetics, Calreticulin genetics, Thrombocythemia, Essential complications, Myeloproliferative Disorders complications, Thrombocytosis complications, Thrombosis etiology, Thrombosis genetics
- Abstract
We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18-95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets ≥1000 × 10
9 /L) in 16%, leukocytosis (leukocytes >11 × 109 /L) in 16%, and at least one cardiovascular risk factor in 52% of cases. JAK2-mutated patients were older (median 62 years) and CALR-mutated and TN (53 years for both) younger (p < 0.001). Female gender clustered with TN (76%) and JAK2 (67%) vs CALR (46%) mutations (p < 0.001). ExT clustered with CALR (type-2 more than type-1), TN and MPL, and leukocytosis with JAK2 mutation (p < 0.001). In multivariable analysis, risk factors for arterial thrombosis-free survival were age ≥60 years (HR 2.0; p < 0.001) and JAK2 mutation (HR 1.3; p = 0.02) with borderline significance for male gender (p = 0.08) and cardiovascular risk factors (p = 0.08); for venous thrombosis-free survival, JAK2 mutation (HR 1.9; p = 0.03) with borderline significance for venous thrombosis history (p = 0.07); for overall survival, older age (p < 0.001), male gender (HR 1.9; p < 0.001), absolute neutrophil count (ANC) ≥ 8 × 109 /L (HR 1.8; p = 0.01), absolute lymphocyte count (ALC) < 1.7 × 109 /L (HR 1.2; p = 0.03); for myelofibrosis-free survival, CALR mutation (HR 2.7; p < 0.001, particularly for CALR type 1/1-like, HR 3.3) and MPL mutation (HR 3.9; p = 0.001); for leukemia-free survival, older age (p = 0.03). Cytoreductive therapy appeared to mitigate both venous (HR 0.3; p = 0.01) and arterial thrombosis (HR 4; p = 0.04); there was a trend for aspirin in preventing arterial thrombosis recurrence. The current study provides real-world observations in essential thrombocythemia, representing a valid source document for interpreting current literature and planning future studies., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
6. Idiopathic Thrombocytosis in Alpha Thalassemia Trait Patient.
- Author
-
Makkawi M, Alasmari S, Albulym O, and Alkhaldy H
- Subjects
- Adolescent, Humans, Female, Platelet Count, Blood Platelets, Diagnosis, Differential, alpha-Thalassemia diagnosis, Thrombocytosis complications, Thrombocytosis genetics, Thrombocytosis diagnosis
- Abstract
Platelet count increases are typically a reactionary response to one of a variety of pathophysiological events. We present here a case of microcytic hypochromic red blood cells and thrombocytosis in an adolescent female that we have monitored for three years. The patient was positive for alpha thalassemia trait; negative for mutation in Janus kinase 2, calreticulin, or myeloproliferative leukemia virus oncogene; and negative for reactive causes of thrombocytosis. Noticeably, a variant in atypical chemokine receptor 1 ( ACKR1 ) (c.-67T>C, rs2814778) was found to be homozygous. Accordingly, the case was diagnosed as idiopathic thrombocytosis, and treatment was given to restore platelet levels to normal. Our findings highlight the possibility of an unknown association between alpha thalassemia trait and idiopathic thrombocytosis in the presence of ACKR1 mutation, which could be implicated in disease pathogenesis., (© 2024 by the Association of Clinical Scientists, Inc.)
- Published
- 2024
7. Reevaluating Thrombocytosis as a Risk Factor in Free Flap Surgery: Does Timing Matter?
- Author
-
Fisher AH, Jones I, Malta K, Arnold A, Nelson ZJ, and Bonawitz S
- Subjects
- Humans, Retrospective Studies, Postoperative Complications epidemiology, Postoperative Complications etiology, Postoperative Complications surgery, Risk Factors, Free Tissue Flaps, Thrombocytosis complications, Thrombosis etiology, Thrombosis surgery, Venous Thrombosis complications
- Abstract
Introduction: Thrombocytosis, defined as a platelet count >400,000, has been implicated as a risk factor in free flap failure. Despite proposed mechanisms of pedicle thrombosis, recent studies have suggested that thrombocytosis has no effect on free tissue transfer viability. Risk factors that may compromise successful free tissue transfer should be understood and elucidated, with particular attention to thrombocytosis and its conflicting evidence in the literature. We hypothesize that thrombocytosis has no bearing on free flap success or the rates of pedicle thrombosis., Methods: Our institution performed a retrospective chart review on all patients who underwent free flap reconstruction over the past 6 years. Patient demographics, medical history, type and location of free tissue transfer, preoperative platelets, postoperative platelets, and flap outcomes and complications (wound dehiscence, infection, hematoma, seroma, and need for blood transfusion) were recorded. Independent t test, Mann-Whitney U tests, χ2 test, and Fisher exact tests were used to determine P values to compare flap outcomes in patients with thrombocytosis (platelet count >400,000) and those with platelet counts less than 400,000., Results: In our 502-patient cohort, 71 were found to have a platelet count >400,000 (35 preoperatively and 36 postoperatively) and 431 patients had platelet counts <400,000. There were 42 reconstructive failures (flap success rate of 91.6%) and 111 returns to the operating room (OR). For patients with postoperative thrombocytosis, 24 flaps returned to the OR (44.4%), whereas in patients without thrombocytosis, 87 flaps returned to the OR (19.4%; P < 0.001). In patients with postoperative thrombocytosis, 10 OR returns were due to pedicle venous thrombosis (18.5%), in comparison to 10 returns for venous thrombosis in those with normal platelets (2.2%; P < 0.001). There was a small difference in free flap success rates between those with postoperative thrombocytosis and normal platelets, 88.7% versus 92.11%; however, this was not statistically significant ( P = 0.71). The thrombocytosis group had a higher incidence of overall postoperative complications ( P = 0.002)., Conclusions: Thrombocytosis has historically been cited as a risk factor for free flap reconstruction failure with recent conflicting evidence in the literature. In patients with postoperative thrombocytosis, we found an increased risk of venous thrombosis; however, this did not result in increased flap failure. There was an increase in postoperative complications, which corresponds with National Surgical Quality Improvement Program data reported in the literature. We suspect that thrombocytosis is not a harbinger of free flap failure but rather a marker for overall inflammation, which may confer a higher rate of venous thrombosis requiring reoperation and postoperative complications., Competing Interests: Conflicts of interest and sources of funding: The authors have no funding, financial relationships, or conflicts of interest to disclose., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. Diagnostic and prognostic impact of preoperative thrombocytosis in muscle invasive bladder cancer: Any role in clinical practice?
- Author
-
Sretenovic M, Bojanic N, Grozdic Milojevic I, Bumbasirevic U, Radisavcevic D, Bulat P, Sipetic Grujicic S, and Milojevic B
- Subjects
- Humans, Prognosis, Retrospective Studies, Cystectomy methods, Muscles pathology, Urinary Bladder Neoplasms complications, Urinary Bladder Neoplasms surgery, Thrombocytosis complications, Thrombocytosis epidemiology, Carcinoma complications, Carcinoma surgery, Anemia complications, Anemia surgery, Hydronephrosis
- Abstract
Background: Since earlier research suggested a link between preoperative thrombocytosis and poor oncological outcomes in several cancers, the significance of platelet count abnormalities in bladder carcinoma (BC) demands for further investigation., Objective: To assess the prognostic value of preoperative thrombocytosis (PTC) on survival in patients with bladder carcinoma treated by radical cystectomy (RC)., Patients and Methods: Analytical cohort comprised a single-center series of 299 patients who underwent RC for bladder carcinoma was evaluated. A platelet count beyond the threshold of 400 × 10
9 /L was considered thrombocytosis. Along with the Kaplan-Meier survival probability, cox proportional hazard regression models were used., Results: Twenty-eight (9.4%) patients had preoperative thrombocytosis. PTC was associated with gender, tumor stage, tumor grade, lymphovascular invasion, hydronephrosis, anemia (p < 0.001), and hypoalbuminemia (p < 0.001). Preoperative thrombocytosis was strongly linked to worse overall survival (OS) (p = 0.002), and cancer specific survival (CSS) (p = 0.004), according to the Kaplan-Meier method. Throughout the follow-up, a total of 198 (66.2%) patients died, including 170 (56.9%) from BC. For this study population 5-year CSS was 45.8%. Preoperative thrombocytosis was not independently associated with OS (HR 1.168; 95% CI 0.740-1.844; p = 0.504) or CSS (HR 1.060; 95% CI 0.649-1.730; p = 0.816) in multivariate Cox regression analysis. Only tumor stage (HR 2.558; 95% CI 1.675-3.908; p < 0.001), hydronephrosis (HR 1.614; 95% CI 1.173-2.221; p = 0.003), lymph node metastasis (HR 1.555; 95% CI 1.076-2-2.248; p = 0.019), anemia (HR 1.454; 95% CI 1.034-2.046; p = 0.032) and ASA grade (HR 1.375; 95% CI 1.006-1.879; p = 0.046) were independently associated with CSS., Conclusions: In a single-center study of consecutive patients who underwent radical cystectomy for bladder cancer, preoperative thrombocytosis was unable to predict outcomes., (© 2023 Wiley Periodicals LLC.)- Published
- 2023
- Full Text
- View/download PDF
9. Thrombocytosis in 158 cats (2011-2018).
- Author
-
Howard LA, Woolcock AD, Christian JA, and Moore GE
- Subjects
- Cats, Animals, Dogs, Retrospective Studies, Platelet Count veterinary, Thrombocytosis epidemiology, Thrombocytosis veterinary, Thrombocytosis complications, Sarcoma veterinary, Cat Diseases diagnosis, Cat Diseases epidemiology, Cat Diseases etiology, Dog Diseases
- Abstract
Objectives: Thrombocytosis is an uncommon hematologic abnormality that is associated with various physiologic, metabolic, inflammatory and neoplastic conditions in people and dogs. Thrombocytosis is not a well-described abnormality in cats. The objective of this study was to classify thrombocytosis in cats based on underlying disease processes and severity, and to compare this with a control population of cats., Methods: A retrospective study was conducted by reviewing the medical records of cats with increased ( > 600 × 10
3 /µl; thrombocytosis group) and normal (200-600 × 103 /µl; 2:1 age-matched control group) platelet counts between 2011 and 2018. Platelet counts were estimated based on blood smear assessment in all cats. Cats were classified by the severity (mild, moderate or marked) of thrombocytosis. Diagnoses were recorded for all cases, and were classified broadly into either neoplasia, endocrine or inflammatory disease., Results: In total, 158 cats were identified with thrombocytosis, with 315 cats in the control group. Non-neoplastic inflammatory disease was the most common diagnosis in both groups (54.4% in cats with thrombocytosis and 56.2% in controls; P = 0.77); however, gastrointestinal diseases were more common in cats with thrombocytosis (75.6%) when compared with controls (34.5%; P <0.0001). Neoplasia was diagnosed more frequently in cats with thrombocytosis (44.3%) compared with the control group (25.4%; P <0.0001). Round cell tumor was the most common neoplasia diagnosis in both groups, but gastrointestinal and multicentric lymphoma were diagnosed more frequently in cats with thrombocytosis compared with control cats. No association between the severity of thrombocytosis and etiology was identified., Conclusions and Relevance: Thrombocytosis in cats is more commonly associated with gastrointestinal, hepatobiliary or immune-mediated diseases when compared with a control population. Neoplasia, especially multicentric and gastrointestinal lymphoma, was more commonly diagnosed in cats with thrombocytosis when compared with control cats.- Published
- 2023
- Full Text
- View/download PDF
10. Clinical significance of reactive thrombocytosis in the course of acute pancreatitis.
- Author
-
Chiba N, Sugita A, Mizuochi M, Sato J, Saito T, Sakurai A, and Kinoshita K
- Subjects
- Humans, Clinical Relevance, Acute Disease, Pancreatitis, Acute Necrotizing, Thrombocytosis complications, Thrombocytopenia complications
- Abstract
Background: Reactive thrombocytosis occurs secondary to systemic infections, inflammatory, and other conditions. The relationship between thrombocytosis and acute pancreatitis (AP) in inflammatory diseases is uncertain. This study aimed to evaluate the clinical significance of thrombocytosis in AP patients during hospitalization., Methods: Subjects within 48 h of AP onset were consecutively enrolled over 6 years. Platelet counts of ≥ 450,000/µL were defined as thrombocytosis, < 100,000/µL as thrombocytopenia, and other counts as normal. We compared clinical characteristics, including the rate of severe AP (SAP) assessed by the Japanese Severity Score; blood markers, including hematologic and inflammatory factors and pancreatic enzymes during hospitalization; and pancreatic complications and outcomes in the three groups., Results: A total of 108 patients were enrolled. Although, SAP was more common in patients with thrombocytosis and thrombocytopenia (87.9% and 100%, respectively), the differences in lymphocytes and C-reactive protein, lactase dehydrogenase, and antithrombin levels, which are factors of the systemic inflammatory response, and the mean platelet volume, an indicator of platelet activation, were observed among patients with thrombocytosis and thrombocytopenia during hospitalization. Regarding pancreatic complications and outcomes, patients with thrombocytosis and thrombocytopenia had higher acute necrotic collection (ANC), pancreatic necrosis, intestinal paralysis, respiratory dysfunction, and pancreatic-related infection levels than patients with normal platelet levels. The relationship between pancreatic complications and thrombocytosis was assessed by multivariate logistic regression; the odds ratios for development of ANC, pancreatic necrosis and pancreatic-related infections were 7.360, 3.735 and 9.815, respectively., Conclusions: Thrombocytosis during hospitalization for AP suggests development of local pancreatic complications and pancreatic-related infections., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
11. Chronic neutrophilic leukemia associated with thrombocytosis and a CSF3R Q781* nonsense mutation.
- Author
-
Abdulbaki R, Tizro P, Boland JL, Zonouz TH, Aggarwal A, and Nava VE
- Subjects
- Humans, Codon, Nonsense, Signal Transduction, Mutation, Receptors, Colony-Stimulating Factor genetics, Leukemia, Neutrophilic, Chronic genetics, Leukemia, Neutrophilic, Chronic complications, Thrombocytosis genetics, Thrombocytosis complications
- Published
- 2023
- Full Text
- View/download PDF
12. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event-A population based cohort study.
- Author
-
Larsson AE, Andréasson B, Holmberg H, Liljeholm M, and Själander A
- Subjects
- Adult, Humans, Cohort Studies, Retrospective Studies, Polycythemia diagnosis, Polycythemia epidemiology, Polycythemia etiology, Thrombocytosis complications, Thrombocytosis diagnosis, Thrombocytosis epidemiology, Polycythemia Vera complications, Polycythemia Vera diagnosis, Polycythemia Vera epidemiology, Thromboembolism diagnosis, Thromboembolism epidemiology, Thromboembolism etiology, Myeloproliferative Disorders complications, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders epidemiology
- Abstract
Introduction: The management to reduce risk of thromboembolic complications in polycythemia vera and essential thrombocythemia are well established, but for other conditions with elevated hemoglobin, hematocrit, or platelets there are no consensus regarding treatment and follow up., Aims: To assess frequency of elevated blood values in patients with thromboembolic event, how many of these should be investigated further regarding myeloproliferative neoplasm and if the risk of recurrent event is depending on underlying condition., Methods: Retrospective cohort study of 3931 adult patients in the county of Norrbotten, Sweden, with thromboembolism during 2017 and 2018., Results: Of the 3931 patients, 1195 had either elevated Hb, HCT, or platelets fulfilling the 2016 revised WHO criteria for PV and ET, and out of these 411 should be evaluated regarding underlying myeloproliferative neoplasms. Unexplained thrombocytosis and secondary erythrocytosis were associated with the highest rate of recurrent event as well as the most inferior restricted mean survival time., Conclusion: Elevated blood values are common in patients with thromboembolic event and the high risk of recurrent event and inferior restricted mean survival time in patients with unexplained thrombocytosis and secondary erythrocytosis implicates the importance of finding and managing the underlying condition., (© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
13. Ulcerative colitis and thrombocytosis: Case report and literature review.
- Author
-
Zhou Y, Zhu F, Jing D, Wang Q, and Zhou G
- Subjects
- Female, Humans, Adult, Blood Platelets pathology, Inflammation complications, Colitis, Ulcerative complications, Colitis, Ulcerative diagnosis, Colitis, Ulcerative pathology, Thrombocytosis complications, Thromboembolism complications
- Abstract
Rationale: Ulcerative colitis (UC) is an autoimmune disease of unknown etiology, sometimes associated with anemia and thrombocytosis. Platelets (PLTs) play a role in amplifying inflammatory and immune responses in chronic inflammation. This study discusses the diagnosis and treatment of a case of UC combined with secondary thrombocytosis and reviews the relevant literature. We report an interaction between thrombocytosis and UC to raise clinicians' awareness of this condition., Patient Concerns: In the current report, we discuss the case of a 30-year-old female patient who presented with frequent diarrhea and thrombocytosis., Diagnosis: Severe UC combined with intestinal infection was diagnosed based on colonoscopy and intestinal biopsy. The patient had a PLT count >450 × 109/L and was diagnosed with reactive thrombocytosis., Interventions and Outcomes: The patient was discharged from the hospital in remission after receiving vedolizumab and anticoagulant treatment., Lessons: In patients with severe UC with thrombocytosis, clinicians should pay attention to PLTs promoting inflammatory progression, as well as screening for venous thromboembolism risk and prophylactic anti-venous thromboembolism therapy at the time of dosing to avoid adverse effects., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
14. Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy.
- Author
-
Lubega J, Kim TO, Airewele G, Grimes A, Bulsara S, Peckham E, Wanless SR, Haq H, Elyanu P, Musoke P, Lumumba M, Kekitiinwa A, Matshaba M, Scheurer M, and Despotovic J
- Subjects
- Humans, Child, Nevirapine therapeutic use, Lamivudine therapeutic use, Retrospective Studies, Prognosis, Case-Control Studies, Platelet Count, Risk Factors, CD4 Lymphocyte Count, HIV Infections complications, HIV Infections drug therapy, Acquired Immunodeficiency Syndrome complications, Thrombocytopenia epidemiology, Thrombocytopenia chemically induced, Thrombocytopenia complications, Thrombocytosis epidemiology, Thrombocytosis chemically induced, Thrombocytosis complications
- Abstract
Objectives: To establish the incidence, risk factors and correlation with survival of thrombocytopenia and thrombocytosis (T/T) among children with HIV infection (CWH)., Design: A retrospective nested case control study of patients 0-18 years in five Baylor International Pediatric AIDS Initiative (BIPAI) centers in sub-Sahara Africa, 2004-2014., Methods: Clinical and laboratory variables including complete blood counts (CBC) were extracted from the BIPAI electronic medical record system. Incident cases of T/T were identified and frequency-matched on follow-up time with controls with normal platelets. We calculated the prevalence and incidence density of T/T and used conditional logistic regression to evaluate their association with selected clinical variables. We constructed Kaplan-Meier curves and a Cox proportional hazards model to evaluate the impact of T/T on survival., Results: Two thousand, one hundred and nine children were sampled. The incidence density of thrombocytopenia was 1 per 57.9 (95% confidence interval [CI] 50.3-66.8) CWH-years. Thrombocytopenia was higher in children with WHO Stage III/IV, lower in children on zidovudine, and had no association with use of lamivudine or nevirapine, CD4 + suppression, age, and nutrition status. Thrombocytopenia was independently associated with 2.2-fold higher mortality (95% CI 1.62-3.08). The incidence density of thrombocytosis was 1 per 11.4 (95% CI 10.7-12.1) CWH-years. Thrombocytosis was associated with higher CD4 + cell count, younger age, and use of lamivudine or nevirapine, and did not impact survival., Conclusions: Platelet count is a clinically valuable biomarker of HIV clinical progression and mortality. Laboratory studies are necessary to elucidate the mechanisms of T/T., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
15. Long-standing thrombocytosis often precedes thromboembolic complications heralding the diagnosis of essential thrombocythemia.
- Author
-
Stalder G, Da Silva WR, Segot A, Blum S, Grandoni F, and Alberio L
- Subjects
- Humans, Platelet Count, Thrombocythemia, Essential complications, Thrombocythemia, Essential diagnosis, Thrombocytosis complications, Thrombocytosis diagnosis, Thromboembolism etiology, Thromboembolism complications
- Abstract
Competing Interests: Declaration of Competing Interest All authors declare that they have no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
16. Upregulation of Coagulation Factor VIII and Fibrinogen After Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension.
- Author
-
Myllylahti L, Ropponen J, Lax M, Lassila R, and Nykänen AI
- Subjects
- Humans, Factor VIII, Fibrinogen, Up-Regulation, Chronic Disease, Endarterectomy, Anticoagulants, Hypertension, Pulmonary surgery, Pulmonary Embolism, Hemostatics, Thromboembolism, Thrombocytosis complications
- Abstract
Objectives: Chronic thromboembolic pulmonary hypertension (CTEPH) is associated with thrombotic states including elevated coagulation factor VIII (FVIII). Pulmonary endarterectomy (PEA) is the main treatment for CTEPH, and efficient anticoagulation is essential to prevent thromboembolism recurrence after surgery. We aimed to characterize longitudinal changes in FVIII and other coagulation biomarkers after PEA., Methods: Coagulation biomarker levels were measured at baseline and up to 12 months after operation in 17 consecutive patients with PEA. Temporal patterns of coagulation biomarkers, and correlation of FVIII with other coagulation biomarkers, were analyzed., Results: Baseline FVIII levels were elevated in 71% of the patients (mean 216 ± 67 IU/dl). FVIII doubled 7 days after PEA, peaking at 471 ± 87 IU/dl, and gradually returned to respective baseline levels within 3 months. Postoperative fibrinogen levels were also elevated. Antithrombin decreased at 1 to 3 days, D-dimer increased at 1 to 4 weeks, and thrombocytosis was observed at 2 weeks., Conclusions: FVIII is elevated in most patients with CTEPH. After PEA, early but transient elevation of FVIII and fibrinogen, and delayed reactive thrombocytosis, occurs, and warrants careful postoperative anticoagulation to prevent thromboembolism recurrence.
- Published
- 2023
- Full Text
- View/download PDF
17. The prognostic role of pre-cystectomy thrombocytosis in invasive bladder cancer.
- Author
-
Chakra MA, Azoulai D, Moussa M, Ismail K, Peyromaure M, Delongchamps NB, Saighi D, Bailly H, and Duquesne I
- Subjects
- Humans, Cystectomy methods, Prognosis, Retrospective Studies, Urinary Bladder Neoplasms complications, Urinary Bladder Neoplasms surgery, Thrombocytosis complications, Thrombocytosis surgery, Carcinoma, Transitional Cell surgery
- Abstract
Purpose: We aim to evaluate the impact of preoperative thrombocytosis on oncological outcomes in patients with bladder cancer (BC) who undergo radical cystectomy (RC)., Methods: Retrospective data collection of 1092 patients managed by RC for BC from 2 tertiary-care centers was performed. Elevated platelet count (PLT) was defined as > 450 × 10
9 /L. Univariable and multivariable logistic regression analyses were used to investigate the impact of thrombocytosis on oncological outcomes. These outcomes were also compared using Kaplan-Meier survival analysis., Results: The median follow-up was 50 months (32-64 months). Thrombocytosis was detected in 18.6% of the patients. The 3-year cancer-specific survival (CSS) for patients with normal PLT count was 92% which was higher than those with elevated PLT count (55%, P < 0.001). Similar results were found for the 6-year CSS with 82% for the no thrombocytosis group and 27% for the thrombocytosis group. Thrombocytosis was still significantly associated with poor prognosis for overall survival and recurrence-free survival (P < 0.001). In the multivariate analysis, CSS was significantly lower in patients with thrombocytosis (HR = 1.71, 95% CI = 1.22-2.39, P = 0.002). Patients with elevated PLT counts were also significantly more likely to receive adjuvant chemotherapy, to have a T stage > pT2b (P = 0.024), to have a positive lymph node, to have variant histology and positive resection margins, and to have concomitant carcinoma in situ (CIS) on final pathology (all P < 0.001)., Conclusions: Preoperative thrombocytosis was valuable for predicting the oncological outcomes of patients undergoing RC for BC., (© 2022. The Author(s), under exclusive licence to Springer Nature B.V.)- Published
- 2022
- Full Text
- View/download PDF
18. Preoperative Thrombocytosis is Not Associated with Overall Survival in 309 Glioblastoma Patients.
- Author
-
Marx S, Altmann R, Baschin M, Paland H, Rauch B, Kohlmann T, and Schroeder HWS
- Subjects
- Humans, Prognosis, Retrospective Studies, Fibrinogen, Aspirin, Glioblastoma complications, Glioblastoma surgery, Brain Neoplasms complications, Brain Neoplasms surgery, Thrombocytosis complications
- Abstract
Background: In recent years, a correlation of thrombocytosis and a worse prognosis was shown for many solid cancers, including glioblastoma multiforme (GBM)., Methods: A retrospective review was performed for all patients with a histologically proven and first-diagnosed GBM between 2005 and 2015 in our department. Clinical and paraclinical parameters were acquired from patient documentation and structured for subsequent data analysis. The association of potential risk factors with overall survival was assessed using the Kaplan-Meier survival analysis and Cox regression., Results: The present study includes 309 patients first diagnosed with primary GBM. Our analyses validate well-known risk factors of a decreased overall survival such as higher patient age, a larger preoperative tumor volume, Karnofsky performance status, extent of resection, tumor localization, and adjuvant treatment. However, no correlation was observed between a preoperative thrombocytosis, the mean platelet volume, leucocyte count, activated partial thromboplastin time (apTT), fibrinogen level, and acetylsalicylic acid 100 co-medication. Patients with preoperative hemoglobin below 7.5 mmol/L had decreased overall survival., Conclusion: The present study, enrolling the largest numbers of patients assessing this topic to date, did not find any association between a preoperative thrombocytosis and overall survival in 309 patients with GBM., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
19. Thrombocytosis predicts poor prognosis of Asian patients with colorectal cancer: A systematic review and meta-analysis.
- Author
-
Xia S, Wu W, Yu L, Ma L, Chen S, and Wang H
- Subjects
- Disease-Free Survival, Female, Humans, Platelet Count, Prognosis, Colorectal Neoplasms pathology, Thrombocytosis complications
- Abstract
Background: There is no study analyzing and evaluating the prognostic role of thrombocytosis in Asian patients with colorectal cancer (CRC)., Methods: A systematic search of articles (PubMed, Embase, and the Cochrane Library) was performed to identify studies using the terms Platelet count, Thrombocytosis, Thrombocytoses, Thrombocythemia or Thrombocythemias with colon, colonic, rectal, rectum, colorectal and prognostic, prognosis, survival or outcome., Results: Thirteen eligible studies with 3964 patients were included. Thrombocytosis was associated with a poorer overall survival (HR of 1.88 [95% CI: 1.24-2.85; P = .003] with univariate analyses, HR of 2.07 [95% CI: 1.2-3.56; P = .008] with multivariate analyses), disease-free survival (HR of 2.58 [95% CI: 1.87-3.57; P < .00001] with multivariate analyses) and cancer specific survival (HR of 2.55 [95% CI: 1.68-3.85; P < .00001]) in Asian patients with CRC. Thrombocytosis had a significant association with female gender, tumor location in the colon, higher pathological T-stage, pathological positive N-stage, but not with lymphatic involvement and venous involvement., Conclusion: The present meta-analysis demonstrates that thrombocytosis is a potentially useful tool for predicting poor survival in Asian patients with CRC, especially for overall survival., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
20. Liver cancer concurrent with chronic myelocytic leukemia and extreme thrombocytosis: a rare case report.
- Author
-
Han P, Han ZQ, Mao X, Wang J, Li QL, Xiao M, Meng L, Tian DA, and Hong ZY
- Subjects
- Female, Fusion Proteins, bcr-abl genetics, Humans, Hydroxyurea therapeutic use, Imatinib Mesylate therapeutic use, In Situ Hybridization, Fluorescence, alpha-Fetoproteins, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Liver Neoplasms complications, Thrombocytosis complications
- Abstract
Chronic myelocytic leukemia (CML) can occasionally occur after long-term chemotherapy for solid tumors; solid tumors secondary to chemotherapy and biotherapy for CML have also been reported. However, concurrence of these two phenomena in an untreated patient has seldom been reported. Herein, we describe the case of a female patient in her early 60 s who was transferred to the liver surgery department after the discovery of a large liver mass and elevated plasma alpha-fetoprotein levels. She was initially diagnosed with liver cancer. Blood tests indicated an increased platelet count (2464 × 10
9 /L). Chromosomal examination from a bone marrow biopsy indicated the presence of the t(9;22) translocation, and subsequent fluorescence in situ hybridization and PCR were positive for the BCR-ABL rearrangement. A diagnosis of CML was made. The patient received hydroxyurea and imatinib to treat CML and underwent subsequent platelet-lowering therapy and a liver biopsy, which suggested moderately poorly differentiated adenocarcinoma or potentially hepatic metastatic carcinoma. However, the patient refused further pathological examination or screening for the site of the primary tumor. She died 6.5 months after discharge. The exact relationship between the two tumors remains unclear, and more patients need to be evaluated.- Published
- 2022
- Full Text
- View/download PDF
21. Markedly increased small-sized megakaryocytes and platelets count in the circulation with pseudo-hyperkalemia following splenectomy.
- Author
-
Li G, Wang B, Li D, Zhu R, and Chen X
- Subjects
- Blood Platelets, Humans, Megakaryocytes, Potassium, Splenectomy adverse effects, Hyperkalemia complications, Myeloproliferative Disorders complications, Thrombocytosis complications
- Abstract
Megakaryocytes are common in the bone marrow and appear less often in circulation. Most studies on circulatory megakaryocytes have implicated myelodysplastic syndromes and myeloproliferative disorders because of disruption of the bone marrow barrier and extramedullary hematopoiesis that is commonly seen in the spleen. As myeloproliferative disorders progress, particularly in the absence of the spleen, it is very likely that considerable numbers of megakaryocytes are present in the circulation. Myeloproliferation is associated with essential thrombocytosis or leukocytosis and is the leading cause of pseudo-hyperkalemia followed by reactive thrombocytosis due to splenectomy, rheumatoid arthritis, and renal cancer. The simultaneous measurement of plasma potassium is required when the platelet count exceeds 500 × 10
9 /L and the level of serum potassium is > 5.4 mmol/L., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
22. Cytokine pathway variants modulate platelet production: IFNA16 is a thrombocytosis susceptibility locus in humans.
- Author
-
Gnatenko DV, Liu Z, Hearing P, Sohn SY, Hu Y, Falanga A, Wu S, Malone LE, Zhu W, and Bahou WF
- Subjects
- Humans, Cytokines, Megakaryocytes, Thrombopoiesis genetics, Myeloproliferative Disorders genetics, Thrombocytosis complications, Thrombocytosis genetics
- Abstract
Inflammatory stimuli have divergent effects on peripheral platelet counts, although the mechanisms of thrombocytopenic and thrombocytotic responses remain poorly understood. A candidate gene approach targeting 326 polymorphic genes enriched in thrombopoietic and cytokine signaling pathways was applied to identify single nucleotide variants (SNVs) implicated in enhanced platelet responses in cohorts with reactive thrombocytosis (RT) or essential (myeloproliferative neoplasm [MPN]) thrombocytosis (ET). Cytokine profiles incorporating a 15-member subset, pathway topology, and functional interactive networks were distinct between ET and RT, consistent with distinct regulatory pathways of exaggerated thrombopoiesis. Genetic studies using aggregate (ET + RT) or ET-restricted cohorts identified associations with 2 IFNA16 (interferon-α16) SNVs, and the ET associations were validated in a second independent cohort (P = .0002). Odds ratio of the combined ET cohort (n = 105) was 4.92, restricted to the JAK2V617F-negative subset (odds ratio, 5.01). ET substratification analysis by variant IFNA16 exhibited a statistically significant increase in IFN-α16 levels (P = .002) among 16 quantifiable cytokines. Recombinantly expressed variant IFN-α16 encompassing 3 linked non-synonymous SNVs (E65H95P133) retained comparable antiviral and pSTAT signaling profiles as native IFN-α16 (V65D95A133) or IFN-α2, although both native and variant IFN-α16 showed stage-restricted differences (compared with IFN-α2) of IFN-regulated genes in CD34+-stimulated megakaryocytes. These data implicate IFNA16 (IFN-α16 gene product) as a putative susceptibility locus (driver) within the broader disrupted cytokine network evident in MPNs, and they provide a framework for dissecting functional interactive networks regulating stress or MPN thrombopoiesis., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
23. Diagnosis and treatment of splenic torsion in children: preoperative thrombocytosis predicts splenic infarction.
- Author
-
Wang Z, Peng C, Wu D, Wang K, and Chen Y
- Subjects
- Child, Female, Humans, Male, Splenectomy adverse effects, Splenectomy methods, Torsion Abnormality diagnosis, Torsion Abnormality diagnostic imaging, Splenic Infarction diagnostic imaging, Splenic Infarction etiology, Thrombocytosis complications, Thrombocytosis diagnosis, Wandering Spleen complications, Wandering Spleen diagnosis, Wandering Spleen surgery
- Abstract
Background: Pediatric splenic torsion is a rare entity, and the most common cause is wandering spleen. This study aimed to summarize our clinical experience in the diagnosis and surgical treatment pediatric patients with splenic torsion, and to use preoperative thrombocytosis as a preoperative predictive factor for splenic infarction., Methods: From January 1st, 2016 to December 31st, 2021, 6 children diagnosed as splenic torsion were included. All patients were surgically treated and followed up. The clinical data was collected including clinical presentations, laboratory tests, imaging results, surgical procedures, and prognosis. Clinical experience of diagnosis and surgical treatment were summarized., Results: There were 4 females and 2 males, with median age at surgery 102.6 (range 9.4-170.7) months. Abdominal pain and abdominal mass were the most common presentations. The diagnosis of splenic torsion depended on imaging studies, and adjacent organ involvement (gastric and pancreas torsion) was observed on contrast CT in one patient. Five patients were diagnosed as torsion of wandering spleen, and one was torsion of wandering accessory spleen. Emergent laparoscopic or open splenectomy was performed in all patients. Pathology revealed total splenic infarction in 4 patients, partial infarction in 1 patient, and viable spleen with congestion and hemorrhage in 1 patient. Preoperative platelet counts were elevated in all 4 patients with splenic infarction, but normal in the rest 2 with viable spleen. Postoperative transient portal vein branch thromboembolism occurred in one patient., Conclusions: Imaging modalities are crucial for the diagnosis of pediatric splenic torsion and adjacent organ involvement. Preoperative thrombocytosis may predict splenic infarction. Spleen preserving surgery should be seriously considered over splenectomy in patients with a viable spleen., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
24. Paraneoplastic syndrome frequency and prognostic effect in hepatocellular carcinoma patients.
- Author
-
Ülger Y and Delik A
- Subjects
- Humans, Prognosis, Retrospective Studies, Severity of Illness Index, alpha-Fetoproteins analysis, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular pathology, End Stage Liver Disease complications, Hypercalcemia complications, Hypercholesterolemia complications, Hypoglycemia etiology, Liver Neoplasms pathology, Paraneoplastic Syndromes diagnosis, Paraneoplastic Syndromes etiology, Polycythemia complications, Thrombocytosis complications
- Abstract
Objective: Symptomatic hepatocellular carcinoma (HCC) patients may generally display constitutional symptoms such as abdominal pain, weight loss, anorexia and localized mass, or atypical clinical features of paraneoplastic syndrome (PNS) such as hypercholesterolemia, hypercalcemia, hypoglycemia, erythrocytosis and thrombocytosis. The most common PNS in HCC is hypercholesterolemia, hypercalcemia, hypoglycemia and erythrocytosis. The aim of this study isto evaluate the relationship of PNS in HCC patients., Material and Method: In this study, the data of 534 patients who were followed up with the diagnosis of HCC between January 2010 and December 2020 in the Gastroenterology clinic were evaluated retrospectively. Clinical data, age, gender, complete blood count of patients with and without PNS, liver biochemistry, alpha-fetoprotein (AFP) level, hepatitis B surface antigen, anti-hepatitis B virus, Child-Pugh score, model for end-stage liver disease score, tumor volume, portal vein thrombosis, liver biopsy histology and radiologic images were taken from the hospital data system and analyzed., Results: Out of the 534 HCC patients, 120 (22.3%) were PNS-positive patients. There was a significant difference between the ages of PNS-positive and PNS-negative patients, and PNS-positive patients were older (64.60±12.97) (P=0.02). PNS-positive HCC was determined as hypoglycemia 5.8%, hypercalcemia 6.3%, erythrocytosis 3.9%, hypercholesterolemia 2.4% and thrombocytosis 3.9%. AFP level (22908 ± 60 ng/ml) and tumor diameter (>10 cm) were higher in the PNS-positive group. Multivariate analysis showed that stage C according to Child-Pugh score and tumor diameter >10 cm were independent predictors of poor prognosis, whereas PNS erythrocytosis and thrombocytosis were independent predictors of better prognosis., Conclusion: In PNS-positive HCC patients, hypoglycemia and hypercalcemia were associated with poor prognosis according to Child-Pugh score, whereas erythrocytosis and thrombocytosis were associated with good prognosis., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Thrombocytosis, haemorrhagic pleural effusion and fibro-infiltrative patches with cavitary lung lesions in a child with COVID-19 pneumonia.
- Author
-
Pachauri A, Singh SN, Verma SK, and Awasthi S
- Subjects
- Adult, Child, Female, Humans, Lung diagnostic imaging, Lung pathology, COVID-19 complications, Pleural Effusion diagnostic imaging, Pleural Effusion etiology, Pneumonia complications, Thrombocytosis complications
- Abstract
COVID-19 infection in children is relatively mild and is associated with fewer complications compared with adults. Here we report the case of a previously healthy preteen girl who presented with active COVID-19 and shock. On day 1, ultrasound of the thorax revealed a right-sided pleural effusion with haemorrhagic pus on diagnostic tap, which improved clinically with appropriate hospital treatment. Even at discharge, the chest X-ray barely changed, indicating a fibrotic area and a collapsed lung. The patient had persistent thrombocytosis, her inflammatory markers (C reactive protein, ESR, interleukin 6, serum ferritin, D-dimer and procalcitonin) were elevated, and a high-resolution CT scan of the thorax at discharge revealed fibro-infiltrative patches with cavitary lesions in COVID-19 pneumonia, which are unusual findings. The patient was discharged on clinical improvement and was doing fine on follow-up after 2 weeks., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
26. [Pseudohyperkalemia: clinical chemistry for the clinician].
- Author
-
Gritter M, Ramakers C, de Man RA, Hoorn EJ, and Rotmans JI
- Subjects
- Adult, Chemistry, Clinical, Female, Humans, Leukocytosis complications, Potassium, Young Adult, Hyperkalemia diagnosis, Hyperkalemia etiology, Thrombocytosis complications
- Abstract
Background: Hyperkalemia is an electrolyte disorder requiring medical attention because it can cause cardiac arrhythmias. Pseudohyperkalemia is the phenomenon of an elevated potassium concentration that is present in the blood sample but not in the patient. Pseudohyperkalemia can be caused by hemolysis, leukocytosis, thrombocytosis, seasonal pseudohyperkalemia, potassium release from muscle cells due to fist clenching during venipuncture, and contamination due to blood withdrawal from an intravenous line over which potassium was administered. Rarer causes include EDTA contamination and familial pseudohyperkalemia., Case Description: A 23-year old woman was admitted with ascites due to polycythemia vera and essential thrombocytosis for which hydroxycarbamide was started. The reported serum potassium concentrations were 6.1 and 6.8 mmol/l. The use of spironolactone was discontinued and she was treated with sodium polystyrene sulfonate and insulin-glucose infusion. The serum potassium concentration only decreased on the ninth day of admission, when the thrombocyte count was normalizing. A diagnosis of pseudohyperkalemia due to thrombocytosis was established., Conclusion: Knowledge of the causes of pseudohyperkalemia and interaction between the clinician and clinical chemist aids in the differentiation between true hyperkalemia and pseudohyperkalemia and may prevent unnecessary diagnostics and harmful treatment.
- Published
- 2022
27. Thrombocytosis and abnormal liver enzymes: A trigger for investigation of underlying malignancy.
- Author
-
Gold LC, Macpherson I, Nobes JH, Dow E, Furrie E, Jamieson S, and Dillon JF
- Subjects
- Humans, Liver Function Tests, Liver Diseases complications, Neoplasms complications, Neoplasms epidemiology, Thrombocytosis complications
- Abstract
Background: Thrombocytosis is often an incidental finding in primary care with a range of causes. Despite evidence of a strong association between thrombocytosis and malignancy, guidelines for investigating thrombocytosis in the absence of red flag symptoms remain unclear. A novel automated system of laboratory analysis, intelligent Liver Function Testing (iLFT), launched in Tayside in 2018 and has identified a patient group with thrombocytosis and abnormal liver test (LFT) results. This study analysed the outcome of these patients and investigated the use of thrombocytosis combined with LFTs in predicting risk of cancer., Methods and Findings: Between August 2018 and August 2020, 6792 patients underwent iLFT, with 246 found to have both thrombocytosis and at least one abnormal LFT. A random case-matched control group of 492 iLFT patients with normal platelet count and at least one abnormal LFT was created. 7.7% (95% CI 4.7-11.8%) of patients with thrombocytosis had cancer compared to 2.0% (1.0-3.7%) of controls. Patients <40 years or with pre-existing causes of thrombocytosis were then excluded. Subsequent analysis revealed a 10.8% (6.6-16.3%) incidence of cancer in thrombocytosis patients (n = 176) compared to 2.5% (1.2-4.6%, p = 0.00014) in patients with normal platelet count (PLT) (n = 398). When thrombocytosis is combined with elevated alkaline phosphatase (ALP), there is a positive predictive value (PPV) of 20% for cancer. These rules were subsequently applied to a validation cohort of 71,652 patients, of whom 458 had thrombocytosis and elevated ALP. There was a 30.6% cancer incidence, confirming the strong predictive value of the combined test of PLT and ALP., Conclusions: These findings suggest a substantial increased risk of cancer in patients with thrombocytosis and raised ALP. This could be developed as an adjunct to current investigation algorithms, highlighting high-risk patients and prompting further investigation (such as computed tomography scans) where indicated., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Eleanor Dow: Funding – Educational grants from Siemens and Abbott unrelated to this paper; Scott Jamieson: Declaration of interest – Reviewer of Scottish Referral Guidelines for Suspected Cancer. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2022
- Full Text
- View/download PDF
28. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts, thrombocytosis, and mutated JAK2/SF3B1 without anemia.
- Author
-
Neumann NM and Wen KW
- Subjects
- Aged, Female, Humans, Mutation, Myelodysplastic-Myeloproliferative Diseases complications, Myelodysplastic-Myeloproliferative Diseases genetics, Thrombocytosis complications, Thrombocytosis genetics, Janus Kinase 2 genetics, Myelodysplastic-Myeloproliferative Diseases pathology, Phosphoproteins genetics, RNA Splicing Factors genetics, Thrombocytosis pathology
- Published
- 2022
- Full Text
- View/download PDF
29. Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients.
- Author
-
Edahiro Y, Kurokawa Y, Morishita S, Yamamoto T, Araki M, and Komatsu N
- Subjects
- Humans, Retrospective Studies, Platelet Count, Thrombocythemia, Essential complications, Thrombocythemia, Essential genetics, Thrombocytosis etiology, Thrombocytosis complications, Myeloproliferative Disorders complications, Thrombosis complications
- Abstract
Objective Thrombocytosis can occur as a primary event accompanying hematological diseases or as a secondary event. Since the publication of the World Health Organization classification in 2008, thrombocytosis is now generally defined as a platelet count above 450×10
9 /L. Furthermore, the discovery of driver-gene mutations in myeloproliferative neoplasms (MPNs) has simplified the diagnostic approach for thrombocytosis. To identify the causes of thrombocytosis using this new definition, we conducted a retrospective study. Methods We identified outpatients and inpatients aged 20 years or older with platelet counts >450×109 /L in a half-year period at a single institute and analyzed the causes of thrombocytosis and associated clinical characteristics. Results Among 1,202 patients with thrombocytosis, 150 (12.5%) had primary and 999 (83.1%) had secondary thrombocytosis. Of these patients with primary thrombocytosis, 129 (86%) had at least 1 molecular marker indicative of MPNs. The major causes of secondary thrombocytosis were tissue injury (32.2%), infection (17.1%), chronic inflammatory disorders (11.7%) and iron deficiency anemia (11.1%). The median platelet count and the incidence of thrombosis were significantly higher in patients with primary thrombocytosis than in those with secondary thrombocytosis. Conclusion Thrombocytosis mainly occurs as a secondary event; however, it is important to determine the cause of and prevent thrombosis, particularly in cases of primary thrombocytosis.- Published
- 2022
- Full Text
- View/download PDF
30. Eltrombopag-Induced Thrombocytosis and Thrombosis in Patients With Antiphospholipid Syndrome and Immune Thrombocytopenic Purpura.
- Author
-
Oo Z, Manvar K, and Wang JC
- Subjects
- Benzoates, Humans, Hydrazines, Pyrazoles, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome drug therapy, Lupus Erythematosus, Systemic complications, Purpura, Thrombocytopenic, Idiopathic chemically induced, Purpura, Thrombocytopenic, Idiopathic complications, Purpura, Thrombocytopenic, Idiopathic drug therapy, Thrombocytopenia chemically induced, Thrombocytopenia complications, Thrombocytosis chemically induced, Thrombocytosis complications, Thrombosis chemically induced
- Abstract
Antiphospholipid syndrome (APS) may be either as a primary or in association with an underlying systemic autoimmune etiology (36.2%), particularly systemic lupus erythematosus (SLE). Thrombocytopenia is infrequently observed in APS patients, with an occurrence of 22% to 42% with the frequency of thrombocytopenia, higher in APS and SLE combination than in primary APS. There have been some controversial reports regarding the treatment of APS syndrome with thrombocytopenia with TPO agonists. We like to report a case with APS syndrome with severe thrombocytopenia treated with TPO-RA and developed severe thrombocytosis and thrombosis. Our case represented the first case of TPO-RA in treating APS syndrome developed severe thrombocytosis and our case also concurred that use of TPO-RA agents should be strongly discouraged in APS until larger studies clarify the safety of TPO-RA agents in APS.
- Published
- 2022
- Full Text
- View/download PDF
31. The effects of plasma viscosity in thromboembolic events among patients with essential thrombocytosis: A case-control study.
- Author
-
Güney T, Can F, Alkan A, Akıncı S, and Dilek İ
- Subjects
- Case-Control Studies, Humans, Viscosity, Thrombocythemia, Essential complications, Thrombocythemia, Essential diagnosis, Thrombocytosis complications, Thrombocytosis diagnosis, Thrombocytosis therapy, Thromboembolism etiology
- Abstract
Introduction: Essential thrombocythemia (ET) is an entity of classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), characterized by thrombocytosis with megakaryocytic hyperplasia where in the thrombocytes are increased with abnormal function.Thrombotic events are seen frequently and represent the main cause of morbidity and mortality in patients with MPNs, mainly polycythemia vera and ET. This study has aimed to research the effects of clonally increased thrombocytes on plasma viscosity (PV) levels among patients with ET and the relationship between PV and thromboembolism history, according to the hypotheses about the effects of PV in thromboembolic events among patients with ET., Methods: A total of 55 patients were enrolled in the study group, 18 of who had been newly diagnosed with ET according to 2016 World Health Organization criteria and had not previously been treated. 37 of them had already been diagnosed with ET and had been treated. There were 47 healthy volunteers in the control group. 5 cc blood samples were taken from the patients into tubes including an anticoagulant to measure their PV levels., Results: PV of the control group was found to be lower than in the study group and both each patient groups (p < 0.05). No relationship was found between the patient groups in terms of PV (p = 0.404). The mean PV levels of the 16 patients with a history of thromboembolism and the 39 patients with no such history were 2.42±0.17 cP and 2.33±0.20 cP, respectively. The mean PV levels were found to be similar according to their history of thromboembolism in all patient groups and in treated patients (p = 0.572 vs p = 0.991)., Conclusion: We have found that PV levels were increased in clonally increased thrombocytes in patients with ET when compared with the control group. This is the first study in this field according to our knowledge.
- Published
- 2022
- Full Text
- View/download PDF
32. Interleukin-6 and thrombopoietin concentrations in dogs with carcinoma with and without thrombocytosis.
- Author
-
Cheney A, Woolcock AD, Mukhopadhyay A, Knapp D, and Moore GE
- Subjects
- Animals, Case-Control Studies, Dogs, Interleukin-6, Platelet Count veterinary, Thrombopoietin, Carcinoma veterinary, Dog Diseases, Thrombocytosis complications, Thrombocytosis veterinary
- Abstract
Background: Carcinoma-associated thrombocytosis involves tumor production of mediators such as interleukin-6 (IL-6) and thrombopoietin (TPO) that increase thrombopoiesis and may play a role in tumor evasion and metastasis. Carcinoma-associated thrombocytosis is described in people, but has not been described in dogs., Hypothesis/objectives: Evaluate the concentrations of IL-6 and TPO in dogs diagnosed with carcinoma with or without thrombocytosis. We hypothesized that IL-6 and TPO concentrations would be higher in dogs with carcinoma compared to healthy dogs, and that IL-6 and TPO concentrations would be higher in dogs with carcinoma and thrombocytosis when compared to dogs with carcinoma and normal platelet counts., Animals: One-hundred sixteen dogs: 63 with carcinoma and 53 healthy control dogs., Methods: Complete blood count was performed in all dogs, and they were stratified for sub-group analysis based on the presence or absence of thrombocytosis (platelet count > 500 103/µL). Serum TPO and IL-6 concentrations were measured by ELISA. Results of selected numeric variables were compared using Wilcoxon rank sum tests for pairwise comparisons. A value of P < .05 was considered significant., Results: Twelve of the dogs with carcinoma (12/63, 19.0%) and none of the healthy control dogs (0%) had thrombocytosis. Thrombopoietin concentrations (median [range]) were significantly higher in dogs with carcinoma when compared to controls (87.42 pg/mL [0 to >600] vs 15.99 pg/mL [0 to >600], P < .001). Interleukin-6 concentrations (median [range]) were not different between dogs with carcinoma and healthy control dogs (9.70 pg/mL [0-181.53] vs 3.03 pg/mL [0-280.77], P = .15). In dogs with carcinoma, the TPO and IL-6 concentrations were not different between dogs with thrombocytosis and dogs with normal platelet count., Conclusions and Clinical Importance: Thrombopoietin concentrations were significantly higher in dogs with carcinoma, regardless of platelet count. Thrombopoietin is likely to be 1 of multiple factors that can impact platelet number, production, and consumption in dogs with carcinoma., (© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)
- Published
- 2022
- Full Text
- View/download PDF
33. Can thrombocytosis or thrombocytopenia predict complicated clinical course and 30-days mortality in patients with pneumonia?
- Author
-
Mısıroğlu RS, Aksay E, Şancı E, and Tertemiz KC
- Subjects
- Adolescent, Aged, Aged, 80 and over, Anemia, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Pneumonia epidemiology, Prognosis, Prospective Studies, Thrombocytopenia epidemiology, Thrombocytosis epidemiology, Treatment Outcome, Hospital Mortality, Pneumonia complications, Thrombocytopenia complications, Thrombocytosis complications
- Abstract
Background/aim: While several different scoring systems aim to determine the clinical outcomes for patients with pneumonia, there is limited emphasis on the platelet count. This study investigated the relationships between thrombocyte count and 30-day mortality and complicated clinical course of patients with pneumonia., Materials and Methods: This prospective cross-sectional study enrolled patients over 18 years old with a diagnosis of pneumonia in the emergency department for six months. The primary outcome was to establish the relationship between platelet count, mortality, complicated clinical course, and initial vital parameters on admission. The secondary outcome was comparing the platelet count with mortality and complicated clinical course during the hospital stay., Results: Four hundred-five patients were included (58.8% male, mean age 75.1 ± 12.7 years). On admission, thrombocytosis was observed in 14.1% and thrombocytopenia in 4.2%. There was no difference between the 30-day mortality according to the platelet count at admission and follow-up. Patients who developed thrombocytopenia during follow-up needed more intensive care admissions, invasive mechanical ventilation, noninvasive mechanical ventilation, and vasopressor treatment, while patients with thrombocytosis needed invasive mechanical ventilation more frequently., Conclusion: Neither thrombocytopenia nor thrombocytosis is not associated with 30-day mortality in ED patients with pneumonia. Thrombocytopenia during follow-up was associated with a higher incidence for a complicated clinical course., Competing Interests: The authors declare that there are no conflicts of interest.
- Published
- 2021
- Full Text
- View/download PDF
34. Acute Basophilic Leukemia Arising from Chronic Myeloid Leukemia with Isolated Thrombocytosis
- Author
-
Zhang Y, Kang X, Chen X, and Li T
- Subjects
- Chronic Disease, Humans, Leukemia, Basophilic, Acute diagnosis, Leukemia, Basophilic, Acute etiology, Leukemia, Myeloid complications, Thrombocytosis complications
- Published
- 2021
- Full Text
- View/download PDF
35. Differential diagnostic and treatment difficulties in a patient with acquired von Willebrand syndrome.
- Author
-
Magyari F, Kracskó B, Bedekovics J, Bereczky Z, Illés Á, and Schlammadinger Á
- Subjects
- Aged, 80 and over, Blood Transfusion, Enzyme Inhibitors therapeutic use, Hemorrhage blood, Hemorrhage complications, Hemorrhage therapy, Humans, Hydroxyurea therapeutic use, Male, Thrombocytosis blood, Thrombocytosis complications, Thrombocytosis therapy, von Willebrand Diseases blood, von Willebrand Diseases complications, von Willebrand Diseases diagnosis, von Willebrand Diseases therapy, von Willebrand Factor analysis
- Abstract
Background: Acquired von Willebrand syndrome (AVWS) is a rare, frequently underdiagnosed and underestimated bleeding disorder. Careful personal and family history and late-onset mucocutaneous bleeding could help clarify the etiology of bleeding deficiency., Case Presentation: An 82-year-old male patient was admitted to our clinic with a severe nosebleed on 30.05.2018. Laboratory results revealed thrombocytosis, elevated white blood cell count and high LDH. Basic coagulation parameters were normal. He was referred to our clinic, where a bone marrow biopsy was taken. His personal and family history had no mention of bleeding disorders, nor was he on anticoagulant therapy. We detected elevated VWF antigen and decreased VWF ristocetin cofactor activity. Loss of high molecular weight multimers was detected by using agarose gel electrophoresis. These laboratory results were indicative of AVWS. Hydroxyurea treatment was initiated, leading to a gradual decrease in platelet count. The histological examination revealed essential thrombocytosist while mutation analysis was JAK2/CALR/MPL negative. However, due to severe nosebleeds, the patient was hospitalized and needed blood transfusion. A cardiological check-up revealed the progression of aortic valve stenosis. After, balloon-dilation a transcatheter aortic valve implantation was performed. As a result, VWF activity and activity to antigen ratio returned to normal as did multimeric structure. In July 2019, the follow-up examination showed that the patient was in a satisfactory condition, with normal hematological parameters, and no new nosebleed episode occurred., Conclusions: The patient complained of recurring nosebleeds, which stopped completely after the resolution of both underlying conditions successful cytoreductive treatment of triple-negative ET and transcatheteric aortic valve replacement.
- Published
- 2021
- Full Text
- View/download PDF
36. Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism.
- Author
-
Lucijanic M, Krecak I, Soric E, Sedinic M, Sabljic A, Derek L, Jaksic O, and Kusec R
- Subjects
- Aged, Aged, 80 and over, Blood Platelets virology, COVID-19 transmission, COVID-19 virology, Female, Humans, Male, Middle Aged, Myeloproliferative Disorders virology, Prognosis, SARS-CoV-2 isolation & purification, Thrombocytosis pathology, Thrombocytosis virology, Venous Thromboembolism etiology, Venous Thromboembolism virology, Blood Platelets pathology, COVID-19 complications, Myeloproliferative Disorders blood, Thrombocytosis complications, Venous Thromboembolism pathology
- Published
- 2021
- Full Text
- View/download PDF
37. Acute and Chronic Hematologic Implications of Emergency and Elective Splenectomy.
- Author
-
Singer KE, Bercz AP, Morris MC, Elson NC, Wallen TE, Hanseman D, Pritts TA, Nomellini V, Patel SH, Makley AT, and Goodman MD
- Subjects
- Humans, Leukocyte Count, Platelet Count, Postoperative Complications epidemiology, Postoperative Complications etiology, Retrospective Studies, Splenectomy adverse effects, Thrombocytosis complications, Thrombocytosis etiology
- Abstract
Introduction: Thrombocytosis and leukocytosis are common after splenectomy. The potential effect of emergency surgery on these postoperative findings is unknown. We hypothesized that emergency splenectomy leads to a more profound and persistent hematologic change as compared to elective splenectomy., Methods: A retrospective review was conducted of patients who underwent elective or trauma splenectomy. Records were queried for platelet (PLT) and white blood cell (WBC) count prior to splenectomy, on postoperative days 1-5, and at day 14, 1 month, 3 months, 6 months, and 1 year. Complications, including thromboembolic events, infection, need for repeat operation, and readmission within 30 days of discharge, were recorded., Results: 463 patients were identified as being eligible for the study, with 173 patients in the elective cohort and 145 patients in each of the isolated trauma splenectomy and polytrauma cohorts. Both cohorts had peak thrombocytosis at week 2 postoperatively. However, polytrauma patients had a significantly higher peak platelet count (P < 0.01). The PLT:WBC ratio was lower in both trauma cohorts pre-operatively and postoperative day 1. Trauma splenectomy had a higher PLT:WBC ratio on days 2 and 3 whereas polytrauma had a lower ratio on days 4 and 5. Emergency cases had greater reoperation and infection rates, whereas elective cases were more likely to require readmission. Postoperative thromboembolic events were only higher in the polytrauma cohort., Conclusions: While trauma splenectomy resulted in more profound postoperative leukocytosis and thrombocytosis, there was no correlation with timing of infection or risk of thromboembolic events. These findings suggest that thrombocytosis and leukocytosis may be associated with thrombotic and infectious events but their presence alone does not indicate direct risks of concomitant infection or thrombosis., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
38. Clinical applications of thrombopoietin silencing: A possible therapeutic role in COVID-19?
- Author
-
Alentado VJ, Moliterno AR, Srour EF, and Kacena MA
- Subjects
- COVID-19 complications, COVID-19 virology, Humans, Inflammation complications, Inflammation metabolism, Megakaryocytes metabolism, SARS-CoV-2 physiology, Thrombocytosis complications, Thrombocytosis metabolism, Thrombopoiesis genetics, Thrombopoietin metabolism, Thrombosis complications, Thrombosis metabolism, COVID-19 therapy, Gene Silencing, Inflammation genetics, Thrombocytosis genetics, Thrombopoietin genetics, Thrombosis genetics
- Abstract
Thrombopoietin (TPO) is most recognized for its function as the primary regulator of megakaryocyte (MK) expansion and differentiation. MKs, in turn, are best known for their role in platelet production. Research indicates that MKs and platelets play an extensive role in the pathologic thrombosis at sites of high inflammation. TPO, therefore, is a key mediator of thromboinflammation. Silencing of TPO has been shown to decrease platelets levels and rates of pathologic thrombosis in patients with various inflammatory disorders (Barrett et al, 2020; Bunting et al, 1997; Desai et al, 2018; Kaser et al, 2001; Shirai et al, 2019). Given the high rates of thromboinflammmation in the novel coronavirus 2019 (COVID-19), as well as the well-documented aberrant MK activity in affected patients, TPO silencing offers a potential therapeutic modality in the treatment of COVID-19 and other pathologies associated with thromboinflammation. The current review explores the current clinical applications of TPO silencing and offers insight into a potential role in the treatment of COVID-19., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. Extramedullary myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with ring sideroblasts and thrombocytosis.
- Author
-
Kerneves P, Cornet E, and Paubelle E
- Subjects
- Aged, Bone Marrow pathology, Erythroblasts pathology, Humans, Male, Myelodysplastic-Myeloproliferative Diseases complications, Thrombocytosis complications, Hematopoiesis, Extramedullary, Myelodysplastic-Myeloproliferative Diseases pathology, Thrombocytosis pathology
- Published
- 2021
- Full Text
- View/download PDF
40. Incidence of Cancer Among Adults With Thrombocytosis in Ontario, Canada.
- Author
-
Giannakeas V and Narod SA
- Subjects
- Adult, Aged, Cohort Studies, Female, Humans, Incidence, Male, Middle Aged, Ontario epidemiology, Predictive Value of Tests, Retrospective Studies, Biomarkers, Tumor blood, Neoplasms blood, Neoplasms etiology, Thrombocytosis blood, Thrombocytosis complications, Thrombocytosis epidemiology
- Abstract
Importance: Individuals with newly diagnosed cancer often have a high platelet count (thrombocytosis). Whether thrombocytosis is associated with the presence of an undiagnosed cancer remains unknown., Objective: To assess whether a new diagnosis of thrombocytosis is associated with a subsequent risk of cancer among adults., Design, Setting, and Participants: This population-based retrospective cohort study was conducted using linked laboratory data from Ontario, Canada, from January 1, 2007, to December 31, 2017, with follow-up until December 31, 2018. The study cohort included adults aged 40 to 75 years on the date of a routine complete blood count (CBC) test (index test) who had a normal platelet count in the 2 previous years and no history of cancer. Data analysis was performed in December 2020., Exposures: Exposed individuals were those with a platelet count greater than 450 × 109/L. Matched unexposed control individuals had a platelet count within the reference range (150 × 109/L to 450 × 109/L) reported within 30 days of the exposure., Main Outcomes and Measures: Incident cancers within 5 years after diagnosis of thrombocytosis. Absolute and relative risks for cancer associated with thrombocytosis were estimated for all cancers and for cancers at specific sites., Results: Of the 3 386 716 Ontario residents with a recorded routine CBC test result, 53 339 (1.6%) had thrombocytosis and a prior normal platelet count. Among individuals with thrombocytosis, the median age was 59.7 years (interquartile range, 50.2-67.4 years) and 37 349 (70.0%) were women. Among the 51 624 individuals with thrombocytosis included in the matched analysis, 2844 (5.5%) had received a diagnosis of a solid cancer in the 2-year follow-up period and 3869 (7.5%) had received a diagnosis within 5 years. The relative risk (RR) for developing any solid cancer within 2 years was 2.67 (95% CI, 2.56-2.79). Associations were found between thrombocytosis and cancers of the ovary (RR, 7.11; 95% CI, 5.59-9.03), stomach (RR, 5.53; 95% CI, 4.12-7.41), colon (RR, 5.41; 95% CI, 4.80-6.10), lung (RR, 4.41; 95% CI, 4.02-4.85), kidney (RR, 3.64; 95% CI, 2.94-4.51), and esophagus (RR, 3.64; 95% CI, 2.46-5.40)., Conclusions and Relevance: In this cohort study, an increased platelet count was associated with an increased risk of cancer for at least 2 years. The results suggest that individuals with unexplained thrombocytosis should be offered screening for several cancers.
- Published
- 2021
- Full Text
- View/download PDF
41. Coexistent antiphospholipid syndrome and myeloproliferative neoplasm.
- Author
-
Sayar Z, Nallamilli S, Efthymiou M, Lambert J, and Cohen H
- Subjects
- Adolescent, Adult, Aged, Antibodies, Antiphospholipid, Cohort Studies, Female, Humans, Male, Middle Aged, Pregnancy, Recurrence, Young Adult, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Antiphospholipid Syndrome drug therapy, Polycythemia Vera complications, Polycythemia Vera diagnosis, Thrombocytosis complications, Thrombocytosis diagnosis, Thrombosis etiology
- Abstract
Antiphospholipid syndrome (APS) and myeloproliferative neoplasms (MPN) are associated with an increased risk of thrombosis. The optimal management of patients with coexistent APS and MPN has not been defined. A single centre and systematic literature review of patients with coexistent APS and MPN was performed. Cases were divided into two groups based on whether they met international consensus criteria for APS. Of the 12 studies identified, eight were excluded (leaving five of a total 54 patients), as although antiphospholipid antibodies (aPL) were documented, the diagnosis of APS was not conclusively demonstrated. Another ten patients with definite APS were identified at our centre. Fifteen patients (ten females, five males) were therefore included in this analysis (eleven definite APS and four highly likely), median age 44 (range: 13-71) years. Nine had polycythaemia vera and six, essential thrombocythaemia. Thirteen of the 15 patients (86.7%) had thrombotic APS (seven with initial venous events and six arterial) and two (13.3%) had obstetric APS. Nine patients were single-positive, and six double-positive for aPL. None were triple aPL-positive. Four patients at our centre had recurrent thrombotic/obstetric events, including while on anticoagulation/antiplatelet treatment.
- Published
- 2021
- Full Text
- View/download PDF
42. Recognition of thrombotic risk of thrombocytosis in iron deficiency
- Author
-
Al-Samkari H, Kessler CM, and Auerbach M
- Subjects
- Animals, Rats, Anemia, Iron-Deficiency complications, Anemia, Iron-Deficiency diagnosis, Anemia, Iron-Deficiency epidemiology, Thrombocytosis complications, Thrombocytosis diagnosis, Thrombocytosis epidemiology, Thrombosis epidemiology, Thrombosis etiology
- Published
- 2021
- Full Text
- View/download PDF
43. Preoperative anaemia and thrombocytosis predict adverse prognosis in non-metastatic renal cell carcinoma with tumour thrombus.
- Author
-
Xiao R, Xu C, He W, Liu L, Zhang H, Liu C, and Ma L
- Subjects
- Aged, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell secondary, Female, Humans, Kidney Neoplasms mortality, Kidney Neoplasms pathology, Lymphatic Metastasis, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Survival Rate, Anemia complications, Carcinoma, Renal Cell complications, Carcinoma, Renal Cell surgery, Kidney Neoplasms complications, Kidney Neoplasms surgery, Neoplastic Cells, Circulating, Thrombocytosis complications
- Abstract
BACKGROUND : This study aimed to determine the prognostic value of preoperative blood parameters in renal cell carcinoma (RCC) and tumour thrombus (TT) patients that were surgically treated., Method: We retrospectively analysed clinicopathological data and blood parameters of 146 RCC and TT patients that were surgically treated. Univariate or multivariate Cox regression analyses were performed to determine the risk factors associated with progression-free survival (PFS) and overall survival (OS). Kaplan-Meier analysis and logistic regression were performed to study the risk factors. Receiver operating characteristic curves were applied to test improvements in the predictive accuracy of the established prognosis score., Results: On univariate and multivariate analysis, anaemia (HR 2.873, P = 0.008) and lymph node metastasis (HR 4.811, P = 0.015) were independent prognostic factors linked to OS. Besides, thrombocytosis (HR 2.324, P = 0.011), histologic subtype (HR 2.835, P = 0.004), nuclear grade (HR 2.069, P = 0.033), and lymph node metastasis (HR 5.739, P = 0.001) were independent prognostic factors associated with PFS. Kaplan-Meier curves revealed that patients with anaemia exhibited worse OS than those without it (P = 0.0033). Likewise, patients with thrombocytosis showed worse PFS than those without it (P < 0.0001). Adding the anaemia and thrombocytosis to the SSIGN score improved its predictive accuracy related to OS and PFS. Preoperative anaemia was linked to more symptom at presentation (OR 3.348, P = 0.006), longer surgical time (OR 1.005, P = 0.001), more blood loss (OR 1.000, P = 0.018), more transfusion (OR 2.734, P = 0.004), higher thrombus level (OR 4.750, P = 0.004) and higher nuclear grade (OR 3.449, P = 0.001) while thrombocytosis was associated with more symptom at presentation (OR 7.784, P = 0.007)., Conclusions: Preoperative anaemia and thrombocytosis were adverse prognostic factors in non-metastatic RCC patients with TT. Also, both preoperative anaemia and thrombocytosis can be clinically used for risk stratification of non-metastatic RCC and TT patients.
- Published
- 2021
- Full Text
- View/download PDF
44. JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
- Author
-
Yasuda H, Morishita S, Mori Y, Tsukune Y, Inano T, Harada S, and Komatsu N
- Subjects
- Calreticulin genetics, Humans, Leukemia, Myeloid, Acute etiology, Male, Middle Aged, Myelodysplastic-Myeloproliferative Diseases genetics, Phosphoproteins genetics, Primary Myelofibrosis etiology, Prognosis, RNA Splicing Factors genetics, Thrombocytosis genetics, Erythroblasts pathology, Janus Kinase 2 genetics, Leukemia, Myeloid, Acute pathology, Mutation, Myelodysplastic-Myeloproliferative Diseases complications, Primary Myelofibrosis pathology, Thrombocytosis complications
- Published
- 2021
- Full Text
- View/download PDF
45. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
- Author
-
Long B, Shi H, and Zhu C
- Subjects
- Aged, Antimetabolites, Antineoplastic therapeutic use, Bone Marrow drug effects, Decitabine therapeutic use, Female, Humans, Myelodysplastic-Myeloproliferative Diseases drug therapy, Myelodysplastic-Myeloproliferative Diseases genetics, Myelodysplastic-Myeloproliferative Diseases pathology, Thrombocytosis drug therapy, Thrombocytosis genetics, Thrombocytosis pathology, Bone Marrow pathology, Myelodysplastic-Myeloproliferative Diseases complications, Thrombocytosis complications
- Abstract
Objective: Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a new disease entity in the 2016 WHO classification, characterized by anemia, thrombocytosis and bone marrow ring sideroblasts. We herein reported a case of MDS/MPN-RS-T and discuss its clinical characteristics. Methods: A 69-year-old woman presented to our hospital with recurrent dizziness and fatigue. Hematologic investigations, bone marrow analysis and genomic DNA sequencing studies were performed. Results: Peripheral blood testing showed normocytes anemia and thrombocytosis, and bone marrow analysis revealed hypercellular with clusters of megakaryocytes and 95% ring sideroblasts (RS). She had a normal karyotype and was found to have SF3B1 mutations. Decitabine therapy produced a clinical response and disease remission in this patient. Conclusions: Our report provides a definite conceptual framework for a better understanding of the characteristics of MDS/MPN-RS-T.
- Published
- 2020
- Full Text
- View/download PDF
46. Frequency and characteristics of the JAK2 V617F mutation in 23 cerebral venous sinus thrombosis patients with thrombocytosis.
- Author
-
Ma Q
- Subjects
- Humans, Mutation, Janus Kinase 2 genetics, Myeloproliferative Disorders, Sinus Thrombosis, Intracranial diagnostic imaging, Sinus Thrombosis, Intracranial genetics, Thrombocytosis complications, Thrombocytosis genetics
- Abstract
Objective: To analyse the frequency and characteristics of the Janus kinase 2 ( JAK2) V617F mutation in patients with cerebral venous sinus thrombosis (CVST) with thrombocytosis., Methods: The study enrolled CVST patients with thrombocytosis that had undergone JAK2 V617F mutation detection to determine the frequency of the JAK2 V617F mutation in this cohort. Correlations between patient demographics, whole blood cell counts, targeted sequencing results and JAK2 V617F mutation status were determined., Results: A total of 23 patients were enrolled in the study: 11 (47.8%) with the JAK2 V617F mutation and 12 (52.2%) without the JAK2 V617F mutation. The mean platelet count was significantly higher in patients with the JAK2 V617F mutation than in patients without the mutation (478.1 ± 107.4 × 10
9 /l versus 374.4 ± 54.1 × 109 /l, respectively). There were no significant differences in age, sex, white blood cell count or haemoglobin level between the two groups. Other than single nucleotide polymorphisms, no hot-spot mutations associated with myeloid tumours other than the JAK2 V617F mutation were detected in four CVST patients that underwent targeted sequencing., Conclusion: The JAK2 V617F mutation was frequently detected in CVST patients with thrombocytosis and it was associated with higher platelet counts.- Published
- 2020
- Full Text
- View/download PDF
47. Hyposplenism, Hashimoto's Autoimmune Thyroiditis and Overlap Syndrome (Celiac Disease and Autoimmune Hepatitis Type 1).
- Author
-
Balaceanu A, Omer S, Stirban R, Zara O, and Dina I
- Subjects
- Adult, Biopsy, Celiac Disease pathology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 pathology, Duodenum pathology, Fatty Liver complications, Female, Gastritis complications, Hashimoto Disease pathology, Hepatitis, Autoimmune pathology, Humans, Magnetic Resonance Imaging, Thrombocytosis complications, Celiac Disease complications, Hashimoto Disease complications, Hepatitis, Autoimmune complications, Spleen pathology
- Abstract
Hyposplenism is associated with autoimmune diseases, inflammatory bowel disease, severe celiac disease, autoimmune thyroiditis, untreated HIV infection and chronic graft-versus-host disease. The aim of this study was to review the existing data on hyposplenism associated with celiac disease and Hashimoto's autoimmune thyroiditis. Our research was based on a clinical case concerning a 41-year-old female who presented with asthenia, fatigue, dyspepsia and chronic diarrhea. The medical history revealed autoimmune Hashimoto's thyroiditis, type 2 diabetes, fatty liver disease, chronic gastritis and thrombocytosis. Multiple investigations showed hyposplenism and complex autoimmune dysfunction with positive serum markers for celiac disease and type 1 autoimmune hepatitis along with minor symptomatology. The intestinal symptomatology of celiac disease is often hid by hypothyroidism-associated autoimmune thyroiditis. Asymptomatic or minimally symptomatic celiac disease associated with Hashimoto's autoimmune thyroiditis is diagnosed by biomarkers. Hyposplenism in celiac disease can occur regardless of the disease stage, latent or symptomatic., (Copyright © 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
48. Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future.
- Author
-
van Es N, Ay C, and Jara-Palomares L
- Subjects
- Age Factors, Aged, Anemia epidemiology, Blood Platelets metabolism, Chronic Disease, Circulating Tumor DNA blood, Female, Humans, Lung Diseases epidemiology, Male, Middle Aged, Neoplasms, Unknown Primary diagnosis, Neoplastic Cells, Circulating pathology, Proteomics methods, Risk Assessment, Risk Factors, Sex Factors, Thrombocytosis epidemiology, Venous Thromboembolism diagnosis, Anemia complications, Early Detection of Cancer methods, Lung Diseases complications, Neoplasms, Unknown Primary complications, Thrombocytosis complications, Venous Thromboembolism etiology
- Abstract
A strong link between cancer and thrombosis has been well recognized. The occurrence of venous thromboembolism (VTE) can be the first clinical sign of an undiagnosed (i.e., occult) cancer. Cancer is more often diagnosed after unprovoked compared with provoked VTE events, with a reported risk in recent studies of around 5%. Extensive, imaging-based screening strategies to detect occult cancer after unprovoked VTE do not appear to have a clear clinical benefit compared with a more limited cancer screening. To identify patients with unprovoked VTE at high risk of occult cancer, risk factors have been explored and prediction models developed. Relevant risk factors for occult cancer include male sex, age, anemia, chronic lung disease, and thrombocytosis. Studies with preselection of patients based on risk assessment and evaluation of limited versus extensive screening strategies are currently ongoing. Also, novel and promising approaches for early detection of cancer in patients with unprovoked VTE by means of liquid biopsies, which include analysis of circulating tumor cells, cell-free tumor DNA, proteomics, or platelet mRNA sequencing, are currently under investigation. In this review, we provide an overview of the risk of cancer diagnosis after VTE, discuss the studies which investigated different screening strategies for occult cancer, summarize risk factors and risk scoring models for identification of patients at high risk of cancer diagnosis after VTE, and highlight ongoing research to optimize screening and identification of patients at risk of occult cancer, which will shape the future clinical practice., Competing Interests: The authors declare, that they have no conflict of interest., (Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2020
- Full Text
- View/download PDF
49. Thrombocytosis helps to stratify risk of colorectal cancer in patients referred on a 2-week-wait pathway.
- Author
-
Bailey JA, Hanbali N, Premji K, Bunce J, Mashlab S, Simpson JA, Humes DJ, and Banerjea A
- Subjects
- Female, Humans, Male, Platelet Count, Prognosis, Referral and Consultation, Retrospective Studies, Colorectal Neoplasms complications, Colorectal Neoplasms diagnosis, Thrombocytosis complications
- Abstract
Purpose: Primary care studies suggest that thrombocytosis (platelet counts > 400 × 10
9 /L) is associated with an increased risk of colorectal cancer (CRC). We aimed to establish whether this marker has significant stratification value in patients seen in secondary care., Methods: A retrospective review of 2991 patients referred to our colorectal 2-week-wait (2WW) pathway between August 2014 and August 2017. Patient demographics were recorded prospectively, and local electronic records systems were used to retrieve full blood counts (FBC) and cancer diagnoses. Patients with no recent platelet count at the time of referral or incomplete records were excluded., Results: 2236 patients were included in this evaluation. There was no significant difference in the age distribution of those with thrombocytosis and those without. There were significantly more females in the thrombocytosis group (72.1% vs 53.9%, chi-squared 24.63, p < 0.0001). 130 CRCs were detected (5.8%) and patients with thrombocytosis were more likely to have CRC (OR 2.62, 95% CI 1.60-4.30). The CRC diagnosis rate was significantly higher in females with thrombocytosis (10.3% vs 2.9%, chi-squared 19.41, p < 0.0001) and males with thrombocytosis (16.1% vs 7.9%, chi-squared 4.62, p = 0.032)., Conclusion: Thrombocytosis appears to have stratification value in the 2WW population. Further evaluation of its value alone or in combination with other stratification tests is required.- Published
- 2020
- Full Text
- View/download PDF
50. Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer.
- Author
-
Nakao S, Minaguchi T, Itagaki H, Hosokawa Y, Shikama A, Tasaka N, Akiyama A, Ochi H, Matsumoto K, and Satoh T
- Subjects
- Female, Humans, Middle Aged, Prognosis, Retrospective Studies, Survival Analysis, Carcinoma, Ovarian Epithelial complications, Carcinoma, Ovarian Epithelial mortality, Thrombocytosis complications
- Abstract
Background: Thrombocytosis is related to tumor stage and survival in ovarian cancer in addition to the common complications of malignant diseases, such as anemia and inflammation. The aim of our study was to clarify the precise prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer., Methods: We retrospectively analyzed 280 consecutive patients who were treated for epithelial ovarian cancer at our institution between 2001 and 2011., Results: Pretreatment thrombocytosis was observed in 18.9% of all patients and was associated with advanced FIGO stage, primary treatment, operation achievement, histologic subtype, microcytic hypochromic anemia (MHA), and nonmalignant inflammatory condition (P = 0.0018, 0.0028, 0.00050, 0.034, 0.00090 and 0.0022). In the patients who relapsed after primary adjuvant chemotherapy (n = 126), thrombocytosis was associated with a shorter treatment-free interval (TFI) (P = 0.0091). The univariate and multivariate analyses revealed that thrombocytosis was independently associated with TFI and MHA (P = 0.021 and 0.0091). Patients with thrombocytosis had worse progression-free survival (PFS) and overall survival (OS) than those without thrombocytosis (P < 0.0001 and < 0.0001). The multivariate analyses for prognostic factors demonstrated that thrombocytosis was significant for poor PFS and OS (P = 0.0050 and 0.022) independent of stage, histology, primary treatment, operation achievement, nonmalignant inflammatory condition and MHA., Conclusions: The current findings indicate that the detrimental survival impact of pretreatment thrombocytosis in epithelial ovarian cancer may be independent of tumor extent but rather attributed to chemoresistance, further supporting the therapeutic potential of targeting thrombopoietic cytokines in the disease.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.